Asklerol 3% Injection

Product Overview

Asklerol 3% Injection is a pharmaceutical formulation containing Polidocanol as its active component. Presented in ampoule form, this medication is primarily indicated for the management of varicose veins and telangiectasias (spider veins). As a sclerosing agent, Polidocanol functions by inducing endothelial damage within targeted blood vessels, resulting in their occlusion and subsequent resolution. This injectable solution is administered exclusively by qualified medical practitioners, offering a minimally invasive therapeutic approach for patients with superficial venous disorders.

Therapeutic Indications

This medication is specifically indicated for:
• Treatment of varicose veins (dilated superficial veins)
• Management of telangiectasias (spider veins)
• Therapy for superficial venous insufficiency

The pathological mechanism involves venous valve incompetence, leading to blood stasis, venous dilation, and tortuosity. Through chemical sclerotherapy, Asklerol 3% Injection promotes venous fibrosis, thereby improving venous hemodynamics and alleviating associated symptoms including pain, edema, and cosmetic concerns.

Administration Protocol

Asklerol 3% Injection requires professional administration via sclerotherapy technique. The procedural steps include:
1. Pre-procedural antisepsis of the treatment area
2. Potential application of venous tourniquet for enhanced visualization
3. Precise intraluminal injection using fine-gauge needles
4. Post-injection compression to optimize therapeutic outcomes

The injection is performed under aseptic conditions with careful attention to dosage and distribution within target vessels.

Mechanism of Action

The active constituent, Polidocanol, demonstrates detergent-like properties that:
• Induce endothelial damage
• Trigger localized inflammatory response
• Promote venous fibrosis and luminal obliteration
• Facilitate gradual vascular resorption

This cascade of events results in permanent venous occlusion, with subsequent improvement in venous return and cosmetic appearance.

Dosage and Treatment Protocol

The therapeutic regimen is individualized based on:
• Venous diameter and extent
• Anatomical location
• Disease severity

Standard practice involves:
• Ultrasound-guided administration for larger varicosities
• Multiple treatment sessions as clinically indicated
• Post-procedural compression therapy
• Activity modification recommendations

Therapeutic Advantages

Clinical benefits include:
• Effective venous occlusion
• Improved venous hemodynamics
• Symptomatic relief (pain, swelling)
• Cosmetic enhancement
• Minimally invasive approach
• Outpatient procedure feasibility

Adverse Effects

Common treatment-related effects may include:
• Localized discomfort
• Ecchymosis
• Pruritus
• Hyperpigmentation
• Temporary induration

These typically resolve spontaneously within days to weeks. Rare hypersensitivity reactions warrant immediate medical attention.

Precautions and Contraindications

Important safety considerations:
• Contraindicated in Polidocanol hypersensitivity
• Requires caution in allergic diathesis
• Pregnancy/lactation status should be evaluated
• Full medical history disclosure is essential
• Concomitant medication review necessary

Storage Requirements

Proper storage conditions:
• Maintain at controlled room temperature (15-30°C)
• Protect from light and moisture
• Keep in original packaging
• Prevent freezing
• Discard if solution appears turbid or discolored
• Follow local regulations for disposal

Medical Disclaimer

The provided information serves educational purposes only and does not constitute medical advice. While we strive for accuracy, this content:
• Is not exhaustive regarding precautions or interactions
• Should not replace professional medical consultation
• Is intended to supplement physician-patient discussions
• Requires verification with healthcare providers
• May not reflect all current therapeutic guidelines

Always consult qualified healthcare professionals for personalized medical recommendations and treatment decisions.